Education
About Us
Working with TipRanks
Follow Us
Akoya Biosciences (AKYA)
NASDAQ:AKYA
AKYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.39 - $4.79
Previous CloseN/A
Volume11.73K
Average Volume (3M)336.93K
Market Cap
$76.72M
Enterprise Value$183.67M
Total Cash (Recent Filing)-$21.66M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.81
Next Earnings
May 20, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding49,816,357
10 Day Avg. Volume238,960
30 Day Avg. Volume336,928
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.04
Price to Cash Flow (P/CF)-7.10
P/FCF Ratio0.00
Enterprise Value/Market Cap2.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.84
Enterprise Value/Ebitda-4.62
Forecast
1Y Price Target
$2.57Price Target Upside77.24% Upside
Rating ConsensusHold
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Cost SynergiesThe merger is expected to yield approximately $40 million in annual cost synergies by the end of 2026.
Leadership StabilityAKYA's CEO, Brian McKelligon, plans to join the combined company, which is viewed positively given his expertise with AKYA's products and knowledge in oncology.
Merger SynergiesThe combination of Akoya and Quanterix's proteomics platforms is expected to offer a complete solution, particularly with applications in both blood and tissue.
Bears Say
Funding UncertaintyNIH funding uncertainty will likely negatively impact Akoya's U.S. academic research business.
Revenue DeclineRevenue decreased about 19% to $21.3 million in 4Q, and the company's full-year 2024 revenue represented a decline of 15.5%.
Shareholder SkepticismInvestors appear skeptical of the merger synergies, and share price performance may remain muted until the shareholder/merger vote occurs.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AKYA FAQ
What was Akoya Biosciences’s price range in the past 12 months?
Akoya Biosciences lowest stock price was $1.39 and its highest was $4.79 in the past 12 months.
What is Akoya Biosciences’s market cap?
Akoya Biosciences’s market cap is $76.72M.
When is Akoya Biosciences’s upcoming earnings report date?
Akoya Biosciences’s upcoming earnings report date is May 20, 2025 which is in 53 days.
How were Akoya Biosciences’s earnings last quarter?
Akoya Biosciences released its earnings results on Mar 17, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.163 by -$0.007.
Is Akoya Biosciences overvalued?
According to Wall Street analysts Akoya Biosciences’s price is currently Undervalued.
Does Akoya Biosciences pay dividends?
Akoya Biosciences does not currently pay dividends.
What is Akoya Biosciences’s EPS estimate?
Akoya Biosciences’s EPS estimate is -0.21.
How many shares outstanding does Akoya Biosciences have?
Akoya Biosciences has 49,816,357 shares outstanding.
What happened to Akoya Biosciences’s price movement after its last earnings report?
Akoya Biosciences reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.163. Following the earnings report the stock price went up 3.846%.
Which hedge fund is a major shareholder of Akoya Biosciences?
Currently, no hedge funds are holding shares in AKYA
---
Akoya Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.57 (77.24% Upside)
$2.57 (77.24% Upside)
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.68%
12-Months-Change
Fundamentals
Return on Equity
-180.44%
Trailing 12-Months
Asset Growth
-30.69%
Trailing 12-Months
Company Description
Akoya Biosciences
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
---
AKYA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a challenging quarter for Akoya Biosciences, with significant revenue declines and underperformance in instrument sales due to market constraints. However, improvements in operational efficiencies and strategic advancements in the clinical pipeline provide a positive outlook for long-term growth.Read More>---
AKYA Stock 12 Month Forecast
Average Price Target
$2.57
▲(77.24% Upside)
Technical Analysis
Best Analysts Covering AKYA
1 Year
1 Year Success Rate
0/16 ratings generated profit
1 Year Average Return
-40.44%
assigned a buy rating 4 months ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -40.44% per trade.
---